Meeting
2013 ASCO Annual Meeting
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
Authors
Michael Ong
The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Michael Ong , Gianluca Del Conte , Rastislav Bahleda , Joaquin Mateo , Silvia Damian , Antonella Perotti , Nathalie Lassau , Françoise Farace , Jimena Lovosgaldeano , Nina Tunariu , Marie Hospitel , Paola Mariani , Patrick Cohen , Giuseppe Capri , Jean-Charles Soria , Luca Gianni , L Rhoda Molife , Cristiana Sessa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Angiogenesis
Clinical Trial Registration Number
NCT01193595
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2535)
DOI
10.1200/jco.2013.31.15_suppl.2535
Abstract #
2535
Poster Bd #
1C
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
First Author: Hans Gelderblom
First Author: R. Wendel Naumann
Poster
2022 ASCO Annual Meeting
Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress).
First Author: Amita Patnaik
Poster
2022 ASCO Annual Meeting
Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress).
First Author: Nehal J. Lakhani